Advertisement

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor

Dear Editor:

We would to address several challenges that have arisen from the study by Bahrami et al. [1] which can be specifically summarized below.

Several relevant data are missing from the study (Table 1).
Table 1

Missing data from the article by Bahrami et al. [1]

Variables

DME patterns (diffuse/subretinal fluid/cystic changes within neurosensory retina/mixed type) at week 24

Diabetic retinopathy types (proliferative/non-proliferative) at enrollment and at the end of the study

Qualitative status of the two outer retinal layers (e.g., the interdigitation zone and the retinal pigment epithelial band) at baseline and the magnitude of the changes (disruption/absence) in all the four outer retinal layers at week 24

Prevalence of epiretinal membrane at baseline and their changes during the study as potential predictive factors on anatomic and visual outcomes after treatment with aflibercept

Fluorecein angiographic findings (focal leakage from microaneurisms or dilated capillaries,...

Keywords

Vascular Endothelial Growth Factor Bevacizumab Ranibizumab Diabetic Macular Edema Aflibercept 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors have full control of the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Disclosure

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

References

  1. 1.
    Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent macular edema. Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-017-3624-y Google Scholar
  2. 2.
    Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMedGoogle Scholar
  3. 3.
    Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 148:266–271CrossRefGoogle Scholar
  4. 4.
    Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 168(2):290–291PubMedGoogle Scholar
  6. 6.
    Călugaru D, Călugăru M (2017) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol 174(2):175–176CrossRefPubMedGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2017) Ranibizumab for persistent diabetic macular edema after bevacizumab treatment. Eur J Ophthalmol. doi: 10.5301/ejo.5000898 Google Scholar
  8. 8.
    Călugăru D, Călugăru M (2016) Comments to: long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 26(6):171–172Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations